Treatment of Late Abortion: Evacuatio Uteri or Conservative Treatment

NCT ID: NCT00256009

Last Updated: 2006-06-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomize trial: expectation or evacuatio uteri for the treatment after late abortion

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomize trial adressing 200 women consecutively recruited from clinical practice at Rigshospitalet.Expectation: administration of 800 microgram Cytotec half an hour after delivery. Surgery: Evacuation of the uterus

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abortion, Spontaneous Abortion, Induced

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cytotec

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

abortion at gestational age (ultrasound) 14+0 - 20+0

Exclusion Criteria

Allergy to cytotec
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rigshospitalet, Denmark

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lars Alling Møller, MD phd

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lars Alling Møller, Md phd

Role: CONTACT

0045 35451338

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KF 01 279545

Identifier Type: -

Identifier Source: org_study_id